Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID‐19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell

Patients with post‐haemopoietic stem cell transplant or chimeric antigen receptor T ‐cell (CAR‐T) therapy face a significant risk of morbidity and mortality from coronavirus disease 2019 because of their immunosuppressed state. As case numbers in Australia and New Zealand continue to rise, guidance...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Internal medicine journal 2023-01, Vol.53 (1), p.119-125
Hauptverfasser:	Perram, Jacinta, Purtill, Duncan, Bajel, Ashish, Butler, Jason, O'Brien, Tracey, Teh, Benjamin, Gilroy, Nicole, Ho, Phoebe J., Doocey, Richard, Hills, Thomas, Perera, Travis, Douglas, Genevieve, Ramachandran, Shanti, Chee, Lynette, Trotman, Judith, Weinkove, Robert, Keogh, Steven, Fraser, Chris, Cochrane, Tara, Watson, Anne‐Marie, Diamond, Peter, Latimer, Maya, Irving, Ian, Blyth, Emily, Cheah, Chan, Cole, Theresa, Milliken, Sam, Yang, Hung, Greenwood, Matthew, Bardy, Peter, Kennedy, Glen, Larsen, Stephen, Conyers, Rachel, Hamad, Nada
Format:	Artikel
Sprache:	eng
Schlagworte:	allogeneic stem cell transplant autologous stem cell transplant CAR‐T cell Cell therapy Chimeric antigen receptors Coronaviruses COVID-19 Hematopoietic Stem Cell Transplantation Humans Lymphocytes T Morbidity New Zealand - epidemiology Position Paper Receptors, Chimeric Antigen - therapeutic use T-Lymphocytes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!